A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer

Inclusion Criteria:

- Previously untreated, apparently resectable, adenocarcinoma of the pancreas at
registration.

- Age greater than or equal to 18 years

- Medically fit for surgery in the opinion of the treating surgeon

- Ability to provide written informed consent

Exclusion Criteria:

- Patients who are currently pregnant, planning to become pregnant, or breast-feeding.

Note: women of childbearing potential must agree to use a medically accepted form of birth
control including (condoms, diaphragms, cervical cap, an intra-uterine device (IUD),
surgical sterility [tubal ligation or a partner that has undergone a vasectomy], or oral
contraceptives). OR must agree to completely abstain from intercourse for two weeks before
beginning study treatment, during participation in this study, and for 2 weeks after the
final study treatment

- Patients with hypercalcemia (blood levels greater than 11.5 mg/dL). Note: In patients
with GFR 30-60 mL/min by Cockroft-Gault, blood calcium levels must be 9.5 mg/dL or
lower before starting paricalcitol.

- Serum creatinine > 2.5 x ULN OR GFR <30 mL/min by Cockroft-Gault formula . Patients
who, in the opinion of the physician, would not be clinically appropriate for receipt
of the therapy regimen associated with participation.